Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.
Buhl R, Bel E, Bourdin A, Dávila I, Douglass JA, FitzGerald JM, Jackson DJ, Lugogo NL, Matucci A, Pavord ID, Wechsler ME, Kraft M. Buhl R, et al. J Allergy Clin Immunol Pract. 2022 Feb;10(2):422-432. doi: 10.1016/j.jaip.2021.10.059. Epub 2021 Nov 8. J Allergy Clin Immunol Pract. 2022. PMID: 34763123 Free article. Review.
Is Inhaler Technique Adequately Assessed and Reported in Clinical Trials of Asthma and Chronic Obstructive Pulmonary Disease Therapy? A Systematic Review and Suggested Best Practice Checklist.
Dekhuijzen PNR, Levy ML, Corrigan CJ, Hadfield RM, Roche N, Usmani OS, Barnes PJ, Scullion JE, Lavorini F, Corbetta L, Kocks JWH, Cosio BG, Buhl R, Pedersen SE; ADMIT Working Group. Dekhuijzen PNR, et al. Among authors: buhl r. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1813-1824.e1. doi: 10.1016/j.jaip.2022.03.013. Epub 2022 Mar 29. J Allergy Clin Immunol Pract. 2022. PMID: 35364340 Free article.
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Dahl R, et al. Among authors: buhl r. Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435. Thorax. 2010. PMID: 20522841 Clinical Trial.
Against all odds: anti-IgE for intrinsic asthma?
Lommatzsch M, Korn S, Buhl R, Virchow JC. Lommatzsch M, et al. Among authors: buhl r. Thorax. 2014 Jan;69(1):94-6. doi: 10.1136/thoraxjnl-2013-203738. Epub 2013 May 24. Thorax. 2014. PMID: 23709757 Free PMC article.
Severe eosinophilic asthma: a roadmap to consensus.
Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, Quirce S, Virchow JC, Holgate S; expert group of the European Consensus Meeting for Severe Eosinophilic Asthma. Buhl R, et al. Eur Respir J. 2017 May 1;49(5):1700634. doi: 10.1183/13993003.00634-2017. Print 2017 May. Eur Respir J. 2017. PMID: 28461308 Free article. No abstract available.
Two pathways, one patient; UK asthma guidelines.
Fowler SJ, O'Byrne PM, Buhl R, Shaw D. Fowler SJ, et al. Among authors: buhl r. Thorax. 2018 Sep;73(9):797-798. doi: 10.1136/thoraxjnl-2018-211703. Epub 2018 May 3. Thorax. 2018. PMID: 29724867 No abstract available.
546 results